'How's my technique?' Your handwashing habits still need work
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
10 minutes ago
- Globe and Mail
U.S. Department of Justice to Sponsor Cellebrite for FedRAMP ATO
TYSONS CORNER, Va., July 23, 2025 (GLOBE NEWSWIRE) -- Cellebrite (NASDAQ: CLBT), a global leader in premier Digital Investigative solutions for the public and private sectors, today announced the U.S. Department of Justice (DOJ) will serve as the official sponsoring agency for the platform's pursuit of a FedRAMP High authorization. Cellebrite announced its intent to pursue FedRAMP authorization in 2024. In 2025, Cellebrite Government Cloud (CGC) was reviewed by a Third-Party Assessment Organization (3PAO), and the FedRAMP Program Management Office (PMO) prepared a Readiness Assessment Report (RAR), which granted Cellebrite Government Cloud FedRAMP High Ready status. DOJ's sponsorship is the critical step required for Cellebrite Government Cloud (CGC) to advance from its current FedRAMP High Ready designation to 'In Process' status. This marks a major milestone that significantly accelerates Cellebrite's compliance journey towards a full Authorization to Operate (ATO). 'We are proud to offer our U.S. federal customers reliable, secure and cutting-edge cloud solutions that enhance their investigative processes and expedite their missions,' said Erik Sachwitz, General Manager of Cellebrite Federal Solutions, Inc. 'We are grateful to the Justice Department for entrusting us to implement their workflow on the Cellebrite Government Cloud. This milestone marks a significant advancement to our ongoing efforts to deepen our support of U.S. federal agencies.' The Cellebrite Government Cloud (CGC) will launch with a comprehensive suite of digital investigative tools. The initial offering provides U.S. federal agencies secure access to two of the company's market-leading solutions: Cellebrite Inseyets, enabling immediate online access to Cellebrite's latest digital forensics capabilities, and Cellebrite Guardian, for collaborative digital evidence review, sharing and storage. Together, these integrated solutions are designed to deliver greater operational efficiencies, support end-to-end collaboration and strengthen the overall chain of custody to help U.S. federal agencies advance their missions while meeting the scalability and security requirements of national, regional and local public safety customers. By shifting digital investigation workflows to the cloud, agencies and attorneys gain secure, flexible access to evidence from anywhere, while also harnessing advanced analytical capabilities enabled by powerful cloud infrastructure. Demonstrating a commitment to supporting diverse missions and operational environments, Cellebrite ensures agencies will continue to have access to on-premises, hybrid and fully offline solutions, empowering them to operate effectively regardless of their unique requirements. References to Websites and Social Media Platforms References to information included on, or accessible through, websites and social media platforms do not constitute incorporation by reference of the information contained at or available through such websites or social media platforms, and you should not consider such information to be part of this press release. About Cellebrite Cellebrite's (Nasdaq: CLBT) mission is to enable its global customers to protect and save lives by enhancing digital investigations and intelligence gathering to accelerate justice in communities around the world. Cellebrite's AI-powered Digital Investigation Platform enables customers to lawfully access, collect, analyze and share digital evidence in legally sanctioned investigations while preserving data privacy. Thousands of public safety organizations, intelligence agencies, and businesses rely on Cellebrite's digital forensic and investigative solutions—available via cloud, on-premises, and hybrid deployments—to close cases faster and safeguard communities. To learn more, visit us at and find us on social media @Cellebrite. Caution Regarding Forward Looking Statements This document includes 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the United States Private Securities Litigation Reform Act of 1995. Forward looking statements may be identified by the use of words such as 'forecast,' 'intend,' 'seek,' 'target,' 'anticipate,' 'will,' 'appear,' 'approximate,' 'foresee,' 'might,' 'possible,' 'potential,' 'believe,' 'could,' 'predict,' 'should,' 'could,' 'continue,' 'expect,' 'estimate,' 'may,' 'plan,' 'outlook,' 'future' and 'project' and other similar expressions that predict, project or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include, but are not limited to, this marks a major milestone that significantly accelerates Cellebrite's compliance journey towards a full Authorization to Operate (ATO); and we are proud to offer our U.S. federal customers reliable, secure and cutting-edge cloud solutions that enhance their investigative processes and expedite their missions are based on current expectations that are subject to risks and uncertainties. A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to: Cellebrite's ability to continue advancing its FedRAMP activities to achieve full FedRAMP authorization in a timely manner; Cellebrite's ability to keep pace with technological advances and evolving industry standards; Cellebrite's material dependence on the purchase, acceptance and use of its solutions by law enforcement and government agencies; real or perceived errors, failures, defects or bugs in Cellebrite's DI solutions; Cellebrite's failure to maintain the productivity of sales and marketing personnel, including relating to hiring, integrating and retaining personnel; intense competition in all of Cellebrite's markets; the inadvertent or deliberate misuse of Cellebrite's solutions; failure to manage its growth effectively; Cellebrite's ability to introduce new solutions and add-ons; Cellebrite's dependency on its customers renewing their subscriptions and purchasing new subscriptions; the low volume of business Cellebrite conducts via e-commerce; risks associated with the use of artificial intelligence; the risk of requiring additional capital to support the growth of its business; risks associated with Cellebrite's dependency on third parties for supplying components or services and with higher costs or unavailability of materials used to create its hardware product components; fluctuations in foreign currency exchange rates; lengthy sales cycle for some of Cellebrite's solutions; near term declines in new or renewed agreements; risks associated with inability to recruit, train and retain qualified personnel and senior management; the security of Cellebrite's operations and the integrity of its software solutions against cyber-attacks, information technology system breaches or disruptions; risks associated with the negative publicity related to Cellebrite's business and use of its products; risks related to Cellebrite's intellectual property; the regulatory constraints to which Cellebrite is subject; risks associated with Cellebrite's operations in Israel, including the ongoing Israel-Hamas war, the increased tension between Israel and Iran and its proxies, including the ongoing hostilities between Israel and Hezbollah, and the risk of a greater regional conflict; risks associated with different corporate governance requirements applicable to Israeli companies and risks associated with being a foreign private issuer and an emerging growth company; market volatility in the price of Cellebrite's shares; changing tax laws and regulations; risks associated with joint, ventures, partnerships and strategic initiatives; risks associated with Cellebrite's significant international operations, including due to fluctuations in foreign currency exchange rates, rising global inflation and exposure to regions subject to political or economic instability; risks associated with Cellebrite's failure to comply with anti-corruption, trade compliance, anti-money-laundering and economic sanctions laws and regulations; risks relating to the adequacy of Cellebrite's existing systems, processes, policies, procedures, internal controls and personnel for Cellebrite's current and future operations and reporting needs; and other factors, risks and uncertainties set forth in the section titled 'Risk Factors' in Cellebrite's annual report on Form 20-F filed with the SEC on March 18, 2025, and in other documents filed by Cellebrite with the U.S. Securities and Exchange Commission ('SEC'), which are available free of charge at You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made, in this communication or elsewhere. Cellebrite undertakes no obligation to update its forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws. Media Victor Cooper Sr. Director of Corporate Communications + Content Operations +1 404.510.2823 Investor Relations Andrew Kramer Vice President, Investor Relations investors@ +1 973.206.7760
National Post
10 minutes ago
- National Post
As RSV Season Approaches, the Federation of Medical Women of Canada Urges National Response to Protect Infants Across the Country
Article content FMWC's Maternal RSV Task Force releases new white paper highlighting gaps in access and calls for immediate action ahead of RSV season Article content TORONTO — Today, the Federation of Medical Women of Canada (FMWC) released its latest white paper through the Maternal RSV Task Force—a national group of experts in maternal, infant, and public health—highlighting the urgent need for equitable access to maternal RSV prevention across Canada. With the 2025–2026 RSV season approaching, the task force is calling for immediate action to protect infants, especially healthy, full-term newborns who account for the majority of severe RSV cases. Article content Article content Respiratory Syncytial Virus (RSV) is the leading cause of infant hospitalizations in Canada, with 1 in 50 infants hospitalized during their first year of life 1. The RSV virus causes upper and lower respiratory tract infections (LRTI) 2, and babies who develop LRTI in early childhood have almost double the risk of premature death from respiratory disease relative to unaffected individuals. 3 Although two newly approved RSV immunization options have been authorized by Health Canada — a maternal vaccine RSVpreF (Abrysvo™, Pfizer) and a monoclonal antibody for infants nirsevimab (Beyfortus™, Sanofi) — access remains inconsistent across provinces and territories. Article content Ontario is leading by covering both RSVpreF for pregnant women and pregnant people and nirsevimab for infants, yet provinces like B.C. only cover the older monoclonal antibody, palivizumab, for high-risk infants — leaving 98% of infants unprotected and at risk for RSV. 4 'With two safe and effective immunization options now available, we have the tools to protect infants from RSV—but awareness, access, and equity remain critical challenges,' says Dr. Vivien Brown, Family Physician and Co-Chair of the FMWC Maternal RSV Task Force. 'This white paper highlights the urgent need for national coordination, public funding, and ongoing education to ensure that every pregnant woman and pregnant person, regardless of where they live, can protect their infant from this serious and preventable disease.' Article content The white paper outlines 13 short- and long-term recommendations to improve RSV prevention in Canada, including: Article content Public funding for RSV immunization (maternal vaccine year-round; nirsevimab seasonally) Authorizing pharmacists to administer publicly funded vaccines Tailoring education for a range of healthcare providers, including midwives and pharmacists Engaging with manufacturers to clarify the predicted availability of immunization options Implementing a universal, national immunization registry Strengthening national guidance on vaccination and provincial implementation Article content 'This is fundamentally about health equity,' says Dr. Shelley Ross, Family Physician and Co-Chair of the FMWC Maternal RSV Task Force. 'Our hope is that by providing a clear, evidence-based roadmap that outlines the steps we can take as a united healthcare system, we can close the gaps and ensure every infant in Canada has the opportunity to be protected from RSV, regardless of geography or circumstance.' Article content The task force also launched a national hub for healthcare providers and the public, offering up-to-date information and comprehensive educational resources on RSV and RSV protection strategies. Article content The FMWC urges pregnant women and pregnant people to speak with their healthcare providers about RSV prevention options and calls on policymakers to help close the access gap as the upcoming 2025–2026 RSV season begins. Article content For more details on the FMWC Maternal RSV White Paper and its recommendations, please visit Article content About FMWC Article content The Federation of Medical Women of Canada (FMWC) is a national organization recognized for its leadership and advocacy for women's evolving health. We are committed to promoting the well-being and health of women and women-identifying individuals both within the medical profession and society at large. The FMWC has a 100-year history in Canada, is a member of the non-governmental organization (NGO) section of the Department of Global Affairs at the United Nations (UN) and is a member of the Medical Women's International Association (MWIA), making us a part of the Economic and Social Council of the UN (ECOSO). For more information, please visit: Article content _____________________________ 1 Government of Canada. Respiratory syncytial virus (RSV) vaccines: Canadian Immunization Guide. immunization-guide-part-4-active-vaccines/ Updated May 14, 2025. Accessed May 21, 2025. 2 Sanchez-Martinez A, Moore T, Freitas TS, et al. Recent advances in the prevention and treatment of respiratory syncytial virus disease. J Gen Virol. 2025;106(4). doi: 10.1099/jgv.0.002095 3 Zar HJ, Cacho F, Kootbodien T, et al. Early-life respiratory syncytial virus disease and long-term respiratory health. Lancet Respir Med. 2024;12(10):810-821. 4 Paes B, Brown V, Courtney E, et al. Optimal implementation of an Ontario nirsevimab program for respiratory syncytial virus (RSV) prophylaxis: Recommendations from a provincial RSV expert panel. Hum Vaccin Immunother. 2024;20(1):2429236. Article content Article content Article content Article content Article content Contacts Article content Media: Article content Article content Article content Article content
CTV News
40 minutes ago
- CTV News
Trump to outline AI priorities amid tech battle with China
U.S. President Donald Trump in the Oval Office of the White House in Washington. (AP Photo/Alex Brandon) U.S. President Donald Trump's administration is set to release a new artificial intelligence blueprint on Wednesday that aims to relax American rules governing the industry at the center of a technological arms race between economic rivals the U.S. and China. Trump will mark the plan's release with a speech outlining the importance of winning an AI race that is increasingly seen as a defining feature of 21st-century geopolitics, with both China and the U.S. investing heavily in the industry to secure economic and military superiority. According to a summary seen by Reuters, the plan calls for the export of U.S. AI technology abroad and a crackdown on state laws deemed too restrictive to let it flourish, a marked departure from former President Joe Biden's 'high fence' approach that limited global access to coveted AI chips. Top administration officials such as Secretary of State Marco Rubio and White House National Economic Adviser Kevin Hassett are also expected to join the event titled 'Winning the AI Race,' organized by White House AI and crypto czar David Sacks and his co-hosts on the 'All-In' podcast, according to an event schedule reviewed by Reuters. Trump may incorporate some of the plan's recommendations into executive orders that will be signed ahead of his speech, according to two sources familiar with the plans. Trump directed his administration in January to develop the plan. The event will be hosted by the Hill and Valley Forum, an informal supper club whose deep-pocketed members helped propel Trump's campaign and sketched out a road map for his AI policy long before he was elected. Trump is expected to take additional actions in the upcoming weeks that will help Big Tech secure the vast amounts of electricity it needs to power the energy-guzzling data centers needed for the rapid expansion of AI, Reuters previously reported. U.S. power demand is hitting record highs this year after nearly two decades of stagnation as AI and cloud computing data centers balloon in number and size across the country. The new AI plan will seek to bar federal AI funding from going to states with tough AI rules and ask the Federal Communications Commission to assess whether state laws conflict with its mandate, according to the summary. The Trump administration will also promote open-source and open-weight AI development and 'export American AI technologies through full-stack deployment packages' and data center initiatives led by the Commerce Department, according to the summary. Trump is laser-focused on removing barriers to AI expansion, in stark contrast to Biden, who feared U.S. adversaries like China could harness AI chips produced by companies like Nvidia and AMD to supercharge its military and harm allies. Biden, who left office in January, imposed a raft of restrictions on U.S. exports of AI chips to China and other countries that it feared could divert the semiconductors to America's top global rival. Trump rescinded Biden's executive order aimed at promoting competition, protecting consumers and ensuring AI was not used for misinformation. He also rescinded Biden's so-called AI diffusion rule, which capped the amount of American AI computing capacity that some countries were allowed to obtain via U.S. AI chip imports. In May, Trump announced deals with the United Arab Emirates that gave the Gulf country expanded access to advanced artificial intelligence chips from the U.S. after previously facing restrictions over Washington's concerns that China could access the technology. (Reporting by Jarrett Renshaw and Alexandra Alper; Additional reporting by Krystal Hu in New York; Editing by Jamie Freed)
